Correlation between gene polymorphism and opioid efficacy in patients with gastric or intestinal cancer.

OBJECTIVE To explore the correlation between gene polymorphism and opioid efficacy in patients with gastric or intestinal cancer. PATIENTS AND METHODS Fifty-nine patients who underwent laparoscopic surgery for gastric or intestinal cancer under general anesthesia were included and randomly divided into oxycodone (n=30) and sufentanil groups (n=29) by reproducible random number generation method. Single nucleotide polymorphisms (SNPs) of four alleles: μ-opioid receptor gene OPRM1 A118G, cytochrome P450 (CPY450) enzyme system: CPY3A4*1G, CYP3A5*3, and CYP2D6*10 were detected by PCR-pyrosequencing. Patients in sufentanil group received intravenous sufentanil injection during anesthesia induction, intraoperative maintenance, and postoperative analgesia, while those in oxycodone group received oxycodone. Patients' postoperative VAS score, opioid use, and prevalence of adverse reactions were recorded. RESULTS The genotype distribution of OPRM1 A118G, CYP3A4*1G, CYP3A5*3, and CYP2D6*10 in Chinese gastric cancer/intestinal cancer patients accorded with the Hardy-Weinberg law (p>0.05). OPRM1 A118G polymorphism correlated with postoperative VAS score and medication dosage, in oxycodone group (p<0.05), while it didn't with those of sufentanil group. The VAS scores in GG group were higher than that in AA group and AG group at T6-T9, (p<0.05); the postoperative pain remedies times in GG group were more than that in the AA and AG groups (p=0.002). CYP3A4*1G polymorphism related to postoperative VAS score, medication dosage and prevalence of adverse reactions in sufentanil group (p<0.05), while it didn't with those of oxycodone group (p>0.05). The total intraoperative medication in AA group was less than that in GG and GA groups (p<0.01), with a higher prevalence of respiratory depression (p=0.01). Nor was there any correlation of CYP3A5*3 and CYP2D6*10 polymorphisms with the efficacy, postoperative VAS score, pain remedies times, postoperative 24 h medication dosage, or prevalence of adverse reactions in oxycodone and sufentanil groups. CONCLUSIONS Gene polymorphism affects the efficacy and adverse reactions of opioids in patients undergoing laparoscopic gastric or intestinal cancer surgery.

[1]  Yitian Zhou,et al.  Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing Projects , 2017, Clinical pharmacology and therapeutics.

[2]  S. Wexner,et al.  Perspectives on Intravenous Oxycodone for Control of Postoperative Pain , 2016, Pain practice : the official journal of World Institute of Pain.

[3]  H. McLeod,et al.  Clinical Implications of Opioid Pharmacogenomics in Patients With Cancer. , 2015, Cancer control : journal of the Moffitt Cancer Center.

[4]  H. Minkowitz.  A review of sufentanil and the sufentanil sublingual tablet system for acute moderate to severe pain. , 2015, Pain management.

[5]  Lin Lu,et al.  The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis. , 2015, Pain physician.

[6]  P. Toft,et al.  Early visceral pain predicts chronic pain after laparoscopic cholecystectomy , 2014, PAIN®.

[7]  Jae-Gook Shin,et al.  Effects of genetic polymorphisms of OPRM1, ABCB1, CYP3A4/5 on postoperative fentanyl consumption in Korean gynecologic patients. , 2013, International journal of clinical pharmacology and therapeutics.

[8]  S. Kaasa,et al.  Is oxycodone efficacy reflected in serum concentrations? A multicenter, cross-sectional study in 456 adult cancer patients. , 2012, Journal of pain and symptom management.

[9]  P. Fayers,et al.  Influence from genetic variability on opioid use for cancer pain: A European genetic association study of 2294 cancer pain patients , 2011, PAIN.

[10]  K. Candiotti,et al.  Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? , 2010, Current medical research and opinion.

[11]  C. Collard,et al.  Effect of genetic factors on opioid action. , 2009, Current opinion in anaesthesiology.

[12]  Gregory L. Holmquist.  Opioid Metabolism and Effects of Cytochrome P450 , 2009 .

[13]  Li-Rong Zhang,et al.  CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin , 2008, European Journal of Clinical Pharmacology.

[14]  E. Kharasch,et al.  Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites , 2006, Clinical pharmacology and therapeutics.

[15]  P. Jannetto,et al.  Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. , 2005, Journal of analytical toxicology.

[16]  Andrew D. Johnson,et al.  Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G* , 2005, Journal of Biological Chemistry.

[17]  S. Kaasa,et al.  Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network , 2005, Palliative medicine.

[18]  Jun He,et al.  CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[19]  Y. Daali,et al.  Codeine intoxication associated with ultrarapid CYP2D6 metabolism. , 2004, The New England journal of medicine.

[20]  E. Kharasch,et al.  Influence of Hepatic and Intestinal Cytochrome P4503A Activity on the Acute Disposition and Effects of Oral Transmucosal Fentanyl Citrate , 2004, Anesthesiology.

[21]  Ji-Young Park,et al.  OPRM 1 A 118 G Gene Variant and Postoperative Opioid Requirement , 2014 .